Saccharomyces cerevisiae var. boulardii – Probiotic Yeast

The discovery and study of the budding yeast Saccharomyces cerevisiae var. boulardii (Sb) is strictly related to the concept of health promoting microorganisms from food. The first most well-known and popularized throughout Europe assumption of health promoting food containing living microorganisms was yogurt. Appointed in 1888 by Louis Pasteur, Ilya Ilyich Metchnikov working in Paris developed a theory that aging is caused by toxic bacteria in the gut and that lactic acid could prolong life which resulted in popularization of yogurt consumption. Metchnikov received with Paul Ehrlich the Nobel Prize in Medicine in 1908 for his previous work on phagocytosis, which probably promoted his idea of today’s so called functional food further and triggered subsequent research on this subject. Scientists started to look for traditional, regional food products considered good for health. One of them was French scientist Henri Boulard who was in IndoChina in 1920 during cholera outbreak. He observed that some people chewing the skin of lychee and mangosteen or preparing special tea did not develop the symptoms of cholera. This observation lead Henri Boulard to the isolation of a tropical strain of yeast named Saccharomyces boulardii (Sb) from lychee and mangosteen fruit, which is nowadays the only commercialized probiotic yeast.

[1]  J. Peyron,et al.  Modification of Salmonella Typhimurium Motility by the Probiotic Yeast Strain Saccharomyces boulardii , 2012, PloS one.

[2]  I. Castro,et al.  Adhesion on yeast cell surface as a trapping mechanism of pathogenic bacteria by Saccharomyces probiotics. , 2012 .

[3]  Tulasi Satyanarayana,et al.  Microorganisms in Sustainable Agriculture and Biotechnology , 2012, Springer Netherlands.

[4]  D. Baumgart,et al.  Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[5]  S. Guandalini.  Commentary on ‘Probiotics for treating acute infectious diarrhoea’ , 2011 .

[6]  F. Dietrich,et al.  Oxidative Stress Survival in a Clinical Saccharomyces cerevisiae Isolate Is Influenced by a Major Quantitative Trait Nucleotide , 2011, Genetics.

[7]  P. Belhumeur,et al.  Modulation of Morphogenesis in Candida albicans by Various Small Molecules , 2011, Eukaryotic Cell.

[8]  J. Dupont,et al.  Saccharomyces cerevisiae Modulates Immune Gene Expressions and Inhibits ETEC-Mediated ERK1/2 and p38 Signaling Pathways in Intestinal Epithelial Cells , 2011, PloS one.

[9]  D. Czerucka,et al.  Saccharomyces boulardii Improves Intestinal Cell Restitution through Activation of the α2β1 Integrin Collagen Receptor , 2011, PloS one.

[10]  H. Szajewska,et al.  Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment , 2010, Alimentary pharmacology & therapeutics.

[11]  J. Buts,et al.  Interaction of Saccharomyces boulardii with intestinal brush border membranes: key to probiotic effects? , 2010, Journal of pediatric gastroenterology and nutrition.

[12]  S. Ng,et al.  Intestinal dendritic cells: Their role in bacterial recognition, lymphocyte homing, and intestinal inflammation , 2010, Inflammatory bowel diseases.

[13]  C. Surawicz.  Le microbiote dans les diarrhées infectieuses , 2010 .

[14]  E. Im,et al.  Progrès récents dans la recherche sur Saccharomyces boulardii , 2010 .

[15]  C. Surawicz.  [The microbiota and infectious diarrhea]. , 2010, Gastroenterologie clinique et biologique.

[16]  M. Łukaszewicz,et al.  The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407. , 2010, FEMS microbiology letters.

[17]  C. Pothoulakis,et al.  [Recent advances in Saccharomyces boulardii research]. , 2010, Gastroenterologie clinique et biologique.

[18]  M. Wenning,et al.  Differentiation of probiotic and environmental Saccharomyces cerevisiae strains in animal feed , 2010, Journal of applied microbiology.

[19]  M. Łukaszewicz,et al.  Capric Acid Secreted by S. boulardii Inhibits C. albicans Filamentous Growth, Adhesion and Biofilm Formation , 2010, PloS one.

[20]  S. Jonjić,et al.  Modulation of natural killer cell activity by viruses. , 2010, Current opinion in microbiology.

[21]  M. Molina,et al.  Differences in activation of MAP kinases and variability in the polyglutamine tract of Slt2 in clinical and non‐clinical isolates of Saccharomyces cerevisiae , 2010, Yeast.

[22]  L. Mcfarland.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. , 2010, World journal of gastroenterology.

[23]  K. Sigler,et al.  Cell ATP level of Saccharomyces cerevisiae sensitively responds to culture growth and drug-inflicted variations in membrane integrity and PDR pump activity. , 2010, Biochemical and biophysical research communications.

[24]  I. Ferreira,et al.  Brewer's Saccharomyces yeast biomass: characteristics and potential applications , 2010 .

[25]  M. Łukaszewicz,et al.  The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. , 2009, FEMS yeast research.

[26]  C. Pothoulakis.  Review article: anti‐inflammatory mechanisms of action of Saccharomyces boulardii , 2009, Alimentary pharmacology & therapeutics.

[27]  F. Dietrich,et al.  Saccharomyces cerevisiae: Population Divergence and Resistance to Oxidative Stress in Clinical, Domesticated and Wild Isolates , 2009, PloS one.

[28]  A. Kunicka-Styczyńska,et al.  Phenotypic and Genotypic Characterization of Probiotic Yeasts , 2009 .

[29]  H. Szajewska,et al.  Saccharomyces boulardii in childhood , 2009, European Journal of Pediatrics.

[30]  Andreas Günther,et al.  Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics , 2008, Yeast.

[31]  J. Buts.  Twenty-Five Years of Research on Saccharomyces boulardii Trophic Effects: Updates and Perspectives , 2008, Digestive Diseases and Sciences.

[32]  R..  Probiotics in man and animals , 2008 .

[33]  N. Skovgaard.  New trends in emerging pathogens. , 2007, International journal of food microbiology.

[34]  A. Prescha,et al.  Assimilation of omega 3 and omega 6 fatty acids and removing of cholesterol from environment by Saccharomyces cerevisiae and Saccharomyces boulardii strains , 2007 .

[35]  P. Rampal,et al.  Review article: yeast as probiotics –Saccharomyces boulardii , 2007, Alimentary pharmacology & therapeutics.

[36]  L. Stateva,et al.  Genotypic and Physiological Characterization of Saccharomyces boulardii, the Probiotic Strain of Saccharomyces cerevisiae , 2007, Applied and Environmental Microbiology.

[37]  A. Foussat,et al.  Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. , 2006, Gastroenterology.

[38]  C. Pothoulakis,et al.  Saccharomyces boulardii Inhibits ERK1/2 Mitogen-activated Protein Kinase Activation Both in Vitro and in Vivo and Protects against Clostridium difficile Toxin A-induced Enteritis* , 2006, Journal of Biological Chemistry.

[39]  C. Pothoulakis,et al.  Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. , 2006, Biochemical and biophysical research communications.

[40]  J. McCusker.  Saccharomyces cerevisiae: an emerging and model pathogenic fungus. , 2006 .

[41]  J. Buts,et al.  Effects of Saccharomyces boulardii on Intestinal Mucosa , 2006, Digestive Diseases and Sciences.

[42]  M. Mallié,et al.  Typing of Saccharomyces cerevisiae Clinical Strains by Using Microsatellite Sequence Polymorphism , 2005, Journal of Clinical Microbiology.

[43]  J. Buts,et al.  Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated withSaccharomyces boulardii , 1990, Digestive Diseases and Sciences.

[44]  M. Whiteway,et al.  Candida morphogenesis and host-pathogen interactions. , 2004, Current opinion in microbiology.

[45]  Andrew Hayes,et al.  Comparative genomic hybridization provides new insights into the molecular taxonomy of the Saccharomyces sensu stricto complex. , 2004, Genome research.

[46]  G. Mitterdorfer,et al.  Clustering of Saccharomyces boulardii strains within the species S. cerevisiae using molecular typing techniques , 2002, Journal of applied microbiology.

[47]  Pierre Bourlioux,et al.  Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. , 2002, Microbial pathogenesis.

[48]  R. Calderone,et al.  Virulence factors of Candida albicans. , 2001, Trends in microbiology.

[49]  B. Dujon,et al.  Microsatellite Typing as a New Tool for Identification of Saccharomyces cerevisiae Strains , 2001, Journal of Clinical Microbiology.

[50]  C. Leão,et al.  Distinctive electrophoretic isoenzyme profiles in Saccharomyces sensu stricto. , 1999, International journal of systematic bacteriology.

[51]  Gedek Br.  Adherence of Escherichia coli serogroup 0 157 and the Salmonella Typhimurium mutant DT 104 to the surface of Saccharomyces boulardii , 1999 .

[52]  Gedek.  Adherence of Escherichia coli serogroup 0 157 and the Salmonella Typhimurium mutant DT 104 to the surface of Saccharomyces boulardii , 1999, Mycoses.

[53]  J. Mccusker,et al.  Species Identification and Virulence Attributes ofSaccharomyces boulardii (nom. inval.) , 1998, Journal of Clinical Microbiology.

[54]  M. Pfaller,et al.  In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates , 1996, Journal of clinical microbiology.

[55]  C. Pothoulakis,et al.  Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum , 1996, Infection and immunity.

[56]  M. Zeitz,et al.  Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. , 1996, Digestion.

[57]  L. Mcfarland.  Saccharomyces boulardii is not Saccharomyces cerevisiae. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  J. Buts,et al.  Saccharomyces boulardii Enhances Rat Intestinal Enzyme Expression by Endoluminal Release of Polyamines , 1994, Pediatric Research.

[59]  Ronald W. Davis,et al.  Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. , 1994, Genetics.

[60]  M. Craynest,et al.  Response of Human and Rat Small Intestinal Mucosa to Oral Administration of Saccharomyces boulardii , 1986, Pediatric Research.

[61]  R. B. Parker.  Probiotics. The other half of the antibiotics story , 1974 .

[62]  D. Lilly,et al.  Probiotics: Growth-Promoting Factors Produced by Microorganisms , 1965, Science.

[63]  W. Mertz,et al.  Chromium(III) and the glucose tolerance factor. , 1959, Archives of biochemistry and biophysics.

[64]  W. Kollath.  [Nutrition and the tooth system; general review with special reference to vitamins]. , 1953, Deutsche zahnarztliche Zeitschrift.

[65]  L. Rettger,et al.  Studies on the Transformation of the Intestinal Flora, with Special Reference to the Implantation of Bacillus Acidophilus: II. Feeding Experiments on Man. , 1920, Proceedings of the National Academy of Sciences of the United States of America.